Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBSTU:UNC +0.53%90 Cyclically Adjusted PS Ratio is 5.59 as of Jul. 27, 2026, which is 197% above its 10-year median of 1.88. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €212.27 (Modestly Overvalued). Among 537 Biotechnology companies, UCB ranks better than 50.28% on this metric.
As of today (2026-07-27), UCB's current share price is €245.00. UCB's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 was €43.86. UCB's Cyclically Adjusted PS Ratio for today is 5.59.
The historical rank and industry rank for UCB's Cyclically Adjusted PS Ratio or its related term are showing as below:
STU:UNC'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.42 Med: 1.88 Max: 6.27
Current: 5.52
During the past 13 years, UCB's highest Cyclically Adjusted PS Ratio was 6.27. The lowest was 1.42. And the median was 1.88.
STU:UNC's Cyclically Adjusted PS Ratio is ranked better than 50.28% of 537
companies
in the Biotechnology industry
Industry Median: 5.63
vs STU:UNC: 5.52
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
UCB's adjusted revenue per share data of for the fiscal year that ended in Dec25 was €39.864. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €43.86 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
UCB (STU:UNC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
UCB Cyclically Adjusted PS Ratio Related Terms
UCB Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for UCB's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:UNC vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, UCB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where UCB's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
UCB's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 5.59 mean?
UCB (STU:UNC) has a Cyclically Adjusted PS Ratio of 5.59 as of Jul. 27, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on UCB and its competitors. This is 197% above median its historical median of 1.88. Over the past decade, UCB's Cyclically Adjusted PS Ratio has ranged from 1.42 to 6.27. According to the industry distribution chart, UCB ranks #267 out of 537 companies in the Biotechnology industry, placing it in the top 49.7%.
Is UCB's Cyclically Adjusted PS Ratio too high?
UCB's current Cyclically Adjusted PS Ratio of 5.59 is 197% above median its 10-year median of 1.88. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 6.27. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.63. UCB's value of 5.59 is 0.7% below this industry median. Based on the distribution chart, UCB ranks #267 out of 537 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #267 out of 537 companies for Cyclically Adjusted PS Ratio. This puts UCB in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.63. UCB's value of 5.59 is 0.7% below this benchmark. Historically, UCB's own Cyclically Adjusted PS Ratio has ranged from 1.42 to 6.27 over the past decade. While the company's 10-year median is 1.88 vs. the industry median of 5.63, UCB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.63, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current Cyclically Adjusted PS Ratio of 5.59 is 0.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on UCB and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current Cyclically Adjusted PS Ratio is 5.59, which is 197% above median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €212.27, compared to a current price of €245.00 — trading 15.4% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 5.59, which is 197% above median its 10-year median of 1.88 and 0.7% below the Biotechnology industry median of 5.63. UCB's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For UCB (STU:UNC), the current Cyclically Adjusted PS Ratio is 5.59 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of €245.00 is trading 15.4% above its estimated GF Value™ of €212.27.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for STU:UNC:
Cyclically Adjusted PS Ratio: 5.59 (197% above median its 10-year median of 1.88)
GF Value™: €212.27 vs. price of €245.00 (15.4% above fair value)
Industry Position: 0.7% below the Biotechnology median (#267 of 537)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score
Get the complete analysis for STU:UNC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
